PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference
FLORHAM PARK, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies respectively, today announced that its management will present at the B. Riley Securities Virtual Oncology Conference on January 28, 2022.
The presentation will provide an update on three ongoing PDS0101 phase 2 clinical trials. In the Versatile-002 phase 2 clinical trial, PDS Biotech is collaborating with MERCK & Co., to evaluate a combination of PDS0101 and KEYTRUDA® (NCT04260126). Versatile-002 is studying the combination in first-line treatment of recurrent or metastatic head and neck cancer, and in second-line treatment of recurrent or metastatic head and neck cancer in patients who have failed prior checkpoint inhibitor therapy. In addition, the Company is conducting a phase 2 clinical study in both second- and third-line treatment of multiple advanced HPV-associated cancers. This study is being led by the National Cancer Institute (NCI). A third phase 2 clinical trial (IMMUNOCERV) in first-line treatment of locally advanced cervical cancer is being led by The University of Texas, MD Anderson Cancer Center.
The presentation will also provide updates on the progression of two other investigational pipeline immune-oncology products. PDS0102 (Versamune® + TARP) addresses prostate cancer, breast cancer and AML, and PDS0103 (Versamune® + MUC1) addresses multple cancers including breast, colon, lung, and ovarian cancers.
The conference is taking place virtually on January 28, 2022. Details for the presentation are as follows:
B. Riley Securities Virtual Oncology Conference
Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, PDS Biotechnology.
About PDS Biotechnology